{"id":"tch-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Cardiotoxicity (trastuzumab-related)"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TCH combines three agents: docetaxel (a taxane microtubule inhibitor), carboplatin (a platinum-based DNA-damaging agent), and trastuzumab (a HER2-targeted monoclonal antibody). This combination provides both cytotoxic chemotherapy and targeted therapy against HER2-overexpressing breast cancer cells, enhancing treatment efficacy in HER2-positive disease.","oneSentence":"TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:25.857Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (early-stage and metastatic)"}]},"trialDetails":[{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT03662776","phase":"","title":"Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma","status":"ENROLLING_BY_INVITATION","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-31","conditions":"Survivors of Unilateral Retinoblastoma","enrollment":120},{"nctId":"NCT03238495","phase":"PHASE2","title":"Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Qamar Khan","startDate":"2017-08-15","conditions":"HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT02131064","phase":"PHASE3","title":"A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-25","conditions":"Breast Neoplasms","enrollment":444},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225},{"nctId":"NCT00021255","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-04","conditions":"Breast Neoplasms","enrollment":3222},{"nctId":"NCT02934828","phase":"PHASE2","title":"Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-10","conditions":"Breast Cancer","enrollment":230},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT00365365","phase":"PHASE2","title":"Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT00446030","phase":"PHASE2","title":"Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Breast Neoplasms","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TCH chemotherapy","genericName":"TCH chemotherapy","companyName":"Agendia","companyId":"agendia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TCH is a chemotherapy regimen combining docetaxel, carboplatin, and trastuzumab to kill cancer cells and target HER2-positive tumors. Used for HER2-positive breast cancer (early-stage and metastatic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}